My Video Playlist »
Empty Playlist
|
|
|
Mike reports on the Friday stock market, Arena Pharmaceuticals, and a change in the net worth of Americans for the first time...
Mike reports on the Friday stock market, Arena Pharmaceuticals, and a change in the net worth of Americans for the first time in 2 years.
0
|
Mike reports on the Friday stock market, Arena Pharmaceuticals, and a change in the net worth of Americans for the first time... |
|
|
|
|
|
|
May 23: Alli soon hits stores as the first FDA-certified over-the-counter weight loss aid. But even its maker says have an ex...
May 23: Alli soon hits stores as the first FDA-certified over-the-counter weight loss aid. But even its maker says have an extra set of clothes at work if you take it. "On the...
0
|
May 23: Alli soon hits stores as the first FDA-certified over-the-counter weight loss aid. But even its maker says have an ex... |
|
|
|
|
|
|
Brian Mckeon Reviews the CNBC Shows Fast Money Mad Money Options Action For the week of April 27 to May 1 2009 ... Brian Mcke...
Brian Mckeon Reviews the CNBC Shows Fast Money Mad Money Options Action For the week of April 27 to May 1 2009 ... Brian Mckeon Fast Money Mad Options Action Guy Adami Howard Dean...
0
|
Brian Mckeon Reviews the CNBC Shows Fast Money Mad Money Options Action For the week of April 27 to May 1 2009 ... Brian Mcke... |
|
|
|
|
|
|
Brian Mckeon Reviews the CNBC Shows Fast Money Mad Money Options Action For the week of March 30 to April 3 2009 ... Brian Mc...
Brian Mckeon Reviews the CNBC Shows Fast Money Mad Money Options Action For the week of March 30 to April 3 2009 ... Brian Mckeon Fast Money Mad Options Action Guy Adami Karen...
0
|
Brian Mckeon Reviews the CNBC Shows Fast Money Mad Money Options Action For the week of March 30 to April 3 2009 ... Brian Mc... |
|
|
|
|
|
|
Innovation is no longer an elective, but is now part of the core curriculum for success. See how the best companies are using...
Innovation is no longer an elective, but is now part of the core curriculum for success. See how the best companies are using their hunger for change to conquer the challenges of...
0
|
Innovation is no longer an elective, but is now part of the core curriculum for success. See how the best companies are using... |
|
|
|
|
|
|
CNBC's Mike Huckman gets his flu shot.
CNBC's Mike Huckman gets his flu shot.
0
|
CNBC's Mike Huckman gets his flu shot. |
|
|
|
|
|
|
#21-#25 Of his list of Top 100 Traders #21 Pershing Square Capital Management #22 Highest Yielding China Stocks #23 Profunds ...
#21-#25 Of his list of Top 100 Traders #21 Pershing Square Capital Management #22 Highest Yielding China Stocks #23 Profunds UltraSector Oil & Gas Inv ENPIX #24 Bill Miller #25...
0
|
#21-#25 Of his list of Top 100 Traders #21 Pershing Square Capital Management #22 Highest Yielding China Stocks #23 Profunds ... |
|
|
|
|
|
|
Pfizer reaches a deal to buy rival drugmaker Wyeth, reports CNBC's Mike Huckman; with Catherine Arnold, Credit Suisse
Pfizer reaches a deal to buy rival drugmaker Wyeth, reports CNBC's Mike Huckman; with Catherine Arnold, Credit Suisse
0
|
Pfizer reaches a deal to buy rival drugmaker Wyeth, reports CNBC's Mike Huckman; with Catherine Arnold, Credit Suisse |
|
|
|
|
|
|
Sol Barer, chairman and CEO of Celgene, discusses his company's latest drug data and deal with CNBC's Mike Huckman. (CNBC) CN...
Sol Barer, chairman and CEO of Celgene, discusses his company's latest drug data and deal with CNBC's Mike Huckman. (CNBC) CNBC - Celgene - Health - Google - Kent
|
Sol Barer, chairman and CEO of Celgene, discusses his company's latest drug data and deal with CNBC's Mike Huckman. (CNBC) CN... |
|
|
|
|
|
|
Insight on the highly-anticipated results on Celgene's drug to treat multiple myeloma, with CNBC's Mike Huckman. (CNBC) Celge...
Insight on the highly-anticipated results on Celgene's drug to treat multiple myeloma, with CNBC's Mike Huckman. (CNBC) Celgene - CNBC - Multiple myeloma - Cancer - Health
|
Insight on the highly-anticipated results on Celgene's drug to treat multiple myeloma, with CNBC's Mike Huckman. (CNBC) Celge... |
|
|
|
|
|
